ProCE Banner Activity

TOURMALINE-MM2: Oral Ixazomib-Rd vs Placebo-Rd for ASCT-Ineligible Patients With Newly Diagnosed MM

Slideset Download
Conference Coverage
The addition of ixazomib to Rd was reasonably well tolerated and conferred a clinically meaningful, but not statistically significant 13.5-month improvement in PFS compared with the control arm.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology